|
Investor Presentation
|
22 June 2023 at 11:40am
|
|
ATH to present at MST Rare Diseases Rich Returns Forum
|
21 June 2023 at 10:20am
|
|
ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder
|
30 May 2023 at 2:00pm
|
|
First Patient Enrolled in Australia in global Phase 2 Trial
|
10 May 2023 at 10:00am
|
|
Appendix 4C and Quarterly Cash Flow Report
|
27 April 2023 at 2:55pm
|
|
bioMUSE Wearable Sensor Data presented at AAN Annual Meeting
|
26 April 2023 at 10:05am
|
|
Notification of cessation of securities - ATH
|
11 April 2023 at 11:30am
|
|
First Patient Enrolled in UK in Phase II Clinical Trial
|
4 April 2023 at 11:00am
|
|
Change in substantial holding
|
17 March 2023 at 8:40am
|
|
Notice Under Section 708A
|
16 March 2023 at 5:45pm
|
|
Application for quotation of securities - ATH
|
16 March 2023 at 5:35pm
|
|
First Patient Enrolled in USA in Phase II Clinical Trial
|
16 March 2023 at 10:40am
|
|
Proposed issue of securities - ATH
|
15 March 2023 at 4:00pm
|
|
US patent grant and license agreement
|
14 March 2023 at 11:05am
|
|
Investor Webinar Presentation
|
9 March 2023 at 9:35am
|
|
First Patient Enrolled in Europe in Phase II Clinical trial
|
8 March 2023 at 9:40am
|
|
Half Yearly Report and Accounts
|
28 February 2023 at 1:40pm
|
|
Regulatory approval for Phase II trial in France and Austria
|
16 February 2023 at 1:00pm
|
|
Change in substantial holding
|
15 February 2023 at 8:25am
|
|
Notification of cessation of securities - ATH
|
1 February 2023 at 6:50pm
|
|
Appendix 4C and Quarterly Cash Flow Report
|
31 January 2023 at 9:55am
|
|
ATH434 Prevents Brain Cell loss in Parkinsons Animal Model
|
30 January 2023 at 3:50pm
|
|
ATH434 Clinical Trial Launched in Italy
|
25 January 2023 at 10:20am
|
|
ATH434 clinical trial launched in the US
|
9 January 2023 at 12:05pm
|
|
ADS ratio change
|
6 January 2023 at 5:30pm
|
|
Alterity to participate in Sachs Neuroscience Conference
|
3 January 2023 at 10:30am
|
|
New US patent for compounds to treat neurodegeneration
|
29 December 2022 at 12:20pm
|
|
Change of Director's Interest Notice x 4
|
15 December 2022 at 4:00pm
|
|
Notification of cessation of securities - ATH
|
15 December 2022 at 3:40pm
|
|
Change in substantial holding
|
14 December 2022 at 8:40am
|
|
ATH Constitution (amended)
|
16 November 2022 at 9:35am
|
|
Results of Annual General Meeting
|
11 November 2022 at 12:15pm
|
|
Chairman's Address 2022 Annual General Meeting
|
11 November 2022 at 9:55am
|
|
ATH Annual General Meeting Presentation
|
11 November 2022 at 9:20am
|
|
Presentation of bioMUSE urinary symptom profile data
|
7 November 2022 at 12:35pm
|
|
Change in substantial holding
|
4 November 2022 at 8:40am
|
|
Change in substantial holding
|
1 November 2022 at 5:59pm
|
|
Appendix 4C and Quarterly Cash Flow Report
|
28 October 2022 at 4:10pm
|
|
Presentation of bioMUSE MRI data
|
26 October 2022 at 8:50am
|
|
ATH434 Clinical Trial launched in Australia
|
13 October 2022 at 1:25pm
|
|
Notice of Annual General Meeting/Proxy Form
|
13 October 2022 at 9:35am
|
|
Change in substantial holding
|
28 September 2022 at 8:35am
|
|
Wearable Sensor Data from bioMUSE Natural History Study
|
26 September 2022 at 11:10am
|
|
Notice Under Section 708A
|
23 September 2022 at 12:45pm
|
|
Application for quotation of securities - ATH
|
23 September 2022 at 12:30pm
|
|
Proposed issue of securities - ATH
|
21 September 2022 at 2:40pm
|
|
US FDA Approval for IND Application for ATH434 for MSA
|
20 September 2022 at 9:55am
|
|
Alterity Form 20-F and XBRL data filed with SEC
|
1 September 2022 at 9:40am
|
|
Appendix 4G and Corporate Governance Statement 2022
|
31 August 2022 at 6:50pm
|
|
Appendix 4E & Annual Report 2022
|
31 August 2022 at 6:40pm
|
Alterity Therapeutics